CLINICAL TRIALS PROFILE FOR BMS-986165
✉ Email this page to a colleague
Clinical Trials for BMS-986165
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02534636 ↗ | Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis | Completed | Bristol-Myers Squibb | Phase 1 | The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions. This study will be the first time this drug is given to humans, and will be conducted entirely in healthy subjects. It will be run in 4 Parts. Part A will investigate single oral doses of drug. Part B will investigate giving the drug daily for 14 days. Part C will investigate daily doses for 14 days in healthy volunteers with Japanese decent. Part D will investigate whether food, stomach acidity or giving the drug in a capsule makes a difference to the safety and potential use of this drug. |
| NCT02931838 ↗ | Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis | Completed | Bristol-Myers Squibb | Phase 2 | A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165 |
| NCT03004768 ↗ | Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants | Completed | Covance | Phase 1 | An oral dose in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986165 |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for BMS-986165
Condition Name
Clinical Trial Locations for BMS-986165
Trials by Country
Clinical Trial Progress for BMS-986165
Clinical Trial Phase
Clinical Trial Sponsors for BMS-986165
Sponsor Name
